Dalvir Gill

See the following -

Conshohocken-Based Non-Profit Aims to Revolutionize Biopharma

T. J. Sharpe | Philly.com | December 1, 2016

What if the next big thing in biopharma wasn’t produced by one of the big pharma companies that line the Northeast corridor between Philadelphia and New York City, but by a whole bunch of them? Conshohocken-based TransCelerate BioPharma is attempting to accomplish this difficult feat by embracing cooperation instead of competition. It is a 501(c)3 non-profit consortium of 18 pharmaceutical companies (and growing) that works with the FDA and global regulators to advance the industry through collaboration with researchers, industry organizations, and federal oversight agencies...

Read More »

DIA 2014 50th Annual Meeting To Highlight TransCelerate BioPharma Collaboration

Press Release | DIA, TransCelerate | May 6, 2014

Industry leaders in R&D will examine accomplishments, progress and 2014 line extensions. Susan Cantrell, senior vice president and managing director for DIA Americas, will chair the panel discussion “Collaboration in R&D: What’s New for TransCelerate BioPharma?” during DIA’s 2014 50th Annual Meeting at the San Diego Convention Center from June 15 to 19...

Read More »

TransCelerate BioPharma Inc. Releases First Update On Risk-Based Monitoring Of Clinical Trials Initiative, Yields Key Lessons And Training Materials

Press Release | TransCelerate BioPharma Inc. | January 30, 2014

In its continued effort to modernize and streamline the way clinical trials are conducted and monitored, TransCelerate BioPharma Inc. ("TransCelerate") is providing the first update to its position paper outlining a methodology for risk-based site monitoring ("Risk-Based Monitoring" or "RBM") released in June 2013. Read More »

TransCelerate BioPharma Inc. Releases Recommended Approach For Protecting Personal Data In Clinical Study Reports

Press Release | TransCelerate BioPharma Inc. | September 2, 2014

TransCelerate BioPharma Inc. ("TransCelerate") today announced that it has developed a recommended approach for protecting personal data in Clinical Study Reports (CSRs) that are shared with researchers, patients and others. The document describes an approach to apply when redacting or removing personal information from CSRs and other related clinical trial documents...

Read More »

TransCelerate Identifies Pharmacovigilance as an Operational Challenge in Need of Transformation

Press Release | TransCelerate BioPharma Inc. | March 29, 2017

TransCelerate BioPharma Inc. today announced that it has added Pharmacovigilance to its portfolio, establishing two new global initiatives: 1.) Interpretation of Pharmacovigilance Regulations and 2.) Value of Safety Information Data Sources. Both initiatives aim to create solutions that will reduce resource inefficiencies, enhance information exchange with global health authorities and improve patient safety to drive more value for patients...